logo image banner image
Browse all Articles
Browse by Country
Browse by University
Browse by Subject
Browse by Journal
Browse by Author

Sponsor image

Sponsor our database

Main Sponsors:

1. King Saud University

Copyright © 2009 Arab Repository
All rights reserved.

Our Address here
Tel: +44 (0) 7704335354

info@arabrepository.net





Home > Universities/Institutions > King Faisal Specialist Hospital and Research Centre > Full Article:
<< Back
Title: Clinical characteristics and outcome of pediatric patients with stage IV Hodgkin lymphoma. PDF
Author(s): Asim Belgaumi,a Amani A. Al-Kofide,a Yasser Khafaga,b Nicey Joseph,a Rubina Jamil-Malik,a Khawar S. Siddiqui,a Rajeh S. Sabbaha
Source: Hematology - Oncology and Stem Cell Therapy , 2009 , 2 , 1, 278-284

Abstract: BACKGROUND AND OBJECTIVES: While treatment outcomes for patients with Hodgkin lymphoma (HL) have improved remarkably, patients with disseminated disease still have a poorer outcome. Stage IV HL is often repported with other ‘advanced stage’ categories, confusing the specific contribution of disease dissemination to the outcome. This single-institution report looks at characteristics and outcomes of this specific category. PATIENTS AND METHODS: The medical records of pediatric HL patients (<14 years) from 1975 through 2003 were retrospectively reviewed and the data analyzed. RESULTS: Stage IV patients (n=67) had more poor-risk characteristics than patients in stages I-III (n=300) (B symptoms 86.6% vs. 19.3%, bulky disease 57.6% vs. 45.5% and mediastinal mass 77.6% vs. 29.7%; P<.001 for all characteristics). The liver was the most common extralymphatic site (in 51.5% of patients with stage IV diseease. Stage IV patients received chemotherapy (CT) alone (n=55) or combined modality therapy (CMT) (n=12). Fifty-four patients (80.6%) achieved complete remission, 2 (3%) partial remission, 10 (14.9%) had progressive disease and 1 was lost to follow up. Overall survival was 79.4% and event-free survival (EFS) was 63.9% at 5 years. There was a non-significant benefit for CMT (OS=91.7% v. 77.1%, P=.3; EFS=70.7% v. 62.7%, P=.3). Ten of 12 relapsed and only 1 of 10 progressive..

Addresses: aDepartment of Pediatric Hematology/Oncology and the bKing Faisal Cancer Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia..

FullText: Click Here to access the full text
Country Code: SA